Epigenetic regulation in the acute kidney injury to chronic kidney disease transition

Nephrology

Volumn 20, Issue 10, 2015, Pages 736-743

  Rodríguez Romo, Roxana ^a,b   Berman, Nathan ^a,b   Gómez, Arturo ^a,b   Bobadilla, Norma A ^a,b  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

DNA condensation; histone acetylation deacetylation; histones; methylation

Indexed keywords

COMPLEMENT COMPONENT C3; DNA; HISTONE; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA;

ACUTE KIDNEY FAILURE; CHROMATIN STRUCTURE; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; DEACETYLATION; DNA METHYLATION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENETIC REGULATION; HISTONE ACETYLATION; HUMAN; INFLAMMATION; MOLECULAR MECHANICS; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT;

EID: 84941266364     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12521     Document Type: Review

References (62)

1. Baedke J,. The epigenetic landscape in the course of time: Conrad Hal Waddington's methodological impact on the life sciences. Stud. Hist. Philos. Biol. Biomed. Sci. 2013; 44 (4 Pt B): 756-773.
2. Goldberg AD, Allis CD, Bernstein E,. Epigenetics: A landscape takes shape. Cell 2007; 128: 635-638.
3. Felsenfeld G, Groudine M,. Controlling the double helix. Nature 2003; 421: 448-453.
4. García-Robles R, Ayala-Ramírez PA, Perdomo-Velásquez SP,. Epigenética: Definición, bases moleculares e implicacines en la evolución humana. Rev. Ciens. Salud 2012; 10: 59-71.
5. Goll MG, Bestor TH,. Eukaryotic cytosine methyltransferases. Annu. Rev. Biochem. 2005; 74: 481-514.
6. Rodriguez-Dorantes M, Tellez-Ascencio N, Cerbon MA, Lopez M, Cervantes A,. [DNA methylation: An epigenetic process of medical importance]. Rev. Invest. Clin. 2004; 56: 56-71.
7. Fraga MF, Ballestar E, Paz MF, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc. Natl. Acad. Sci. U.S.A. 2005; 102: 10604-10609.
8. Spannhoff A, Kim YK, Raynal NJ, et al. Histone deacetylase inhibitor activity in royal jelly might facilitate caste switching in bees. EMBO Rep. 2011; 12: 238-243.
9. Mattick JS, Makunin IV,. Small regulatory RNAs in mammals. Hum. Mol. Genet. 2005; 14 (Spec1): R121-132.
10. Bellomo R, Kellum JA, Ronco C,. Acute kidney injury. Lancet 2012; 380: 756-766.
11. Beall D, Bywaters EG, Belsey RH, Miles JA,. Crush injury with renal failure. BMJ 1941; 1: 432-434.
12. Thomas ME, Blaine C, Dawnay A, et al. The definition of acute kidney injury and its use in practice. Kidney Int. 2015; 87: 62-73.
13. Section 2: AKI definition. Kidney Int. Suppl. (2011) 2012; 2: 19-36.
14. Ali T, Khan I, Simpson W, et al. Incidence and outcomes in acute kidney injury: A comprehensive population-based study. J. Am. Soc. Nephrol. 2007; 18: 1292-1298.
15. Li PK, Burdmann EA, Mehta RL,. Acute kidney injury: Global health alert. Transplantation 2013; 95: 653-657.
16. Bagshaw SM, George C, Bellomo R,. Early acute kidney injury and sepsis: A multicentre evaluation. Crit. Care 2008; 12: R47.
17. Barrera-Chimal J, Bobadilla NA,. Are recently reported biomarkers helpful for early and accurate diagnosis of acute kidney injury? Biomarkers 2012; 17: 385-393.
18. Rahman M, Shad F, Smith MC,. Acute kidney injury: A guide to diagnosis and management. Am. Fam. Physician 2012; 86: 631-639.
19. Macedo E, Mehta RL,. Prerenal failure: From old concepts to new paradigms. Curr. Opin. Crit. Care 2009; 15: 467-473.
20. Siegel NJ, Devarajan P, Van WS,. Renal cell injury: Metabolic and structural alterations. Pediatr. Res. 1994; 36: 129-136.
21. Basile DP, Anderson MD, Sutton TA,. Pathophysiology of acute kidney injury. Compr. Physiol. 2012; 2: 1303-1353.
22. Nony PA, Schnellmann RG,. Mechanisms of renal cell repair and regeneration after acute renal failure. J. Pharmacol. Exp. Ther. 2003; 304: 905-912.
23. Friedrich JO, Adhikari N, Herridge MS, Beyene J,. Meta-analysis: Low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann. Intern. Med. 2005; 142: 510-524.
24. Mejia-Vilet JM, Ramirez V, Cruz C, Uribe N, Gamba G, Bobadilla NA,. Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone. Am. J. Physiol. Renal Physiol. 2007; 293: F78-86.
25. Ramirez V, Trujillo J, Valdes R, et al. Adrenalectomy prevents renal ischemia-reperfusion injury. Am. J. Physiol. Renal Physiol. 2009; 297: F932-942.
26. Ojeda-Cervantes M, Barrera-Chimal J, Alberu J, Perez-Villalva R, Morales-Buenrostro LE, Bobadilla NA,. Mineralocorticoid receptor blockade reduced oxidative stress in renal transplant recipients: A double-blind, randomized pilot study. Am. J. Nephrol. 2013; 37: 481-490.
27. Sanchez-Pozos K, Barrera-Chimal J, Garzon-Muvdi J, et al. Recovery from ischemic acute kidney injury by spironolactone administration. Nephrol. Dial. Transplant. 2012; 27: 3160-3169.
28. Johannes T, Ince C, Klingel K, Unertl KE, Mik EG,. Iloprost preserves renal oxygenation and restores kidney function in endotoxemia-related acute renal failure in the rat. Crit. Care Med. 2009; 37: 1423-1432.
29. Sims CR, MacMillan-Crow LA, Mayeux PR,. Targeting mitochondrial oxidants may facilitate recovery of renal function during infant sepsis. Clin. Pharmacol. Ther. 2014; 96: 662-664.
30. Coca SG, Singanamala S, Parikh CR,. Chronic kidney disease after acute kidney injury: A systematic review and meta-analysis. Kidney Int. 2012; 81: 442-448.
31. Bucaloiu ID, Kirchner HL, Norfolk ER, Hartle JE, Perkins RM,. Increased risk of death and de novo chronic kidney disease following reversible acute kidney injury. Kidney Int. 2012; 81: 477-485.
32. Lewington AJ, Cerda J, Mehta RL,. Raising awareness of acute kidney injury: A global perspective of a silent killer. Kidney Int. 2013; 84: 457-467.
33. Bedford M, Farmer C, Levin A, Ali T, Stevens P,. Acute kidney injury and CKD: Chicken or egg? Am. J. Kidney Dis. 2012; 59: 485-491.
34. Chawla LS, Amdur RL, Amodeo S, Kimmel PL, Palant CE,. The severity of acute kidney injury predicts progression to chronic kidney disease. Kidney Int. 2011; 79: 1361-1369.
35. Conger JD, Kim GE, Robinette JB,. Effects of ANG II, ETA, and TxA2 receptor antagonists on cyclosporin A renal vasoconstriction. Am. J. Physiol. 1994; 267 (3 Pt 2): F443-449.
36. Brooks DP,. Role of endothelin in renal function and dysfunction. Clin. Exp. Pharmacol. Physiol. 1996; 23: 345-348.
37. Kurata H, Takaoka M, Kubo Y, et al. Protective effect of nitric oxide on ischemia/reperfusion-induced renal injury and endothelin-1 overproduction. Eur. J. Pharmacol. 2005; 517: 232-239.
38. Basile DP,. The endothelial cell in ischemic acute kidney injury: Implications for acute and chronic function. Kidney Int. 2007; 72: 151-156.
39. Basile DP, Donohoe D, Roethe K, Osborn JL,. Renal ischemic injury results in permanent damage to peritubular capillaries and influences long-term function. Am. J. Physiol. Renal Physiol. 2001; 281: F887-F899.
40. Basile DP, Friedrich JL, Spahic J, et al. Impaired endothelial proliferation and mesenchymal transition contribute to vascular rarefaction following acute kidney injury. Am. J. Physiol. Renal Physiol. 2011; 300: F721-F733.
41. Basile DP,. Rarefaction of peritubular capillaries following ischemic acute renal failure: A potential factor predisposing to progressive nephropathy. Curr. Opin. Nephrol. Hypertens. 2004; 13: 1-7.
42. Basile DP, Fredrich K, Chelladurai B, Leonard EC, Parrish AR,. Renal ischemia reperfusion inhibits VEGF expression and induces ADAMTS-1, a novel VEGF inhibitor. Am. J. Physiol. Renal Physiol. 2008; 294: F928-936.
43. Leonard EC, Friedrich JL, Basile DP,. VEGF-121 preserves renal microvessel structure and ameliorates secondary renal disease following acute kidney injury. Am. J. Physiol. Renal Physiol. 2008; 295: F1648-1657.
44. Yang L, Besschetnova TY, Brooks CR, Shah JV, Bonventre JV,. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat. Med. 2010; 16: 535-543, 1p following 143.
45. Bechtel W, McGoohan S, Zeisberg EM, et al. Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat. Med. 2010; 16: 544-550.
46. Johnson AB, Barton MC,. Hypoxia-induced and stress-specific changes in chromatin structure and function. Mutat. Res. 2007; 618: 149-162.
47. Bomsztyk K, Denisenko O,. Epigenetic alterations in acute kidney injury. Semin. Nephrol. 2013; 33: 327-340.
48. Zager RA, Johnson AC,. Renal ischemia-reperfusion injury upregulates histone-modifying enzyme systems and alters histone expression at proinflammatory/profibrotic genes. Am. J. Physiol. Renal Physiol. 2009; 296: F1032-F1041.
49. Naito M, Zager RA, Bomsztyk K,. BRG1 increases transcription of proinflammatory genes in renal ischemia. J. Am. Soc. Nephrol. 2009; 20: 1787-1796.
50. Naito M, Bomsztyk K, Zager RA,. Renal ischemia-induced cholesterol loading: Transcription factor recruitment and chromatin remodeling along the HMG CoA reductase gene. Am. J. Pathol. 2009; 174: 54-62.
51. Li HF, Cheng CF, Liao WJ, Lin H, Yang RB,. ATF3-mediated epigenetic regulation protects against acute kidney injury. J. Am. Soc. Nephrol. 2010; 21: 1003-1013.
52. Pratt JR, Parker MD, Affleck LJ, et al. Ischemic epigenetics and the transplanted kidney. Transplant. Proc. 2006; 38: 3344-3346.
53. Huang N, Tan L, Xue Z, Cang J, Wang H,. Reduction of DNA hydroxymethylation in the mouse kidney insulted by ischemia reperfusion. Biochem. Biophys. Res. Commun. 2012; 422: 697-702.
54. Wing MR, Devaney JM, Joffe MM, et al. DNA methylation profile associated with rapid decline in kidney function: Findings from the CRIC study. Nephrol. Dial. Transplant. 2014; 29: 864-872.
55. Pang M, Kothapally J, Mao H, et al. Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy. Am. J. Physiol. Renal Physiol. 2009; 297: F996-1005.
56. Kazantsev AG, Thompson LM,. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat. Rev. Drug Discov. 2008; 7: 854-868.
57. Marumo T, Hishikawa K, Yoshikawa M, Fujita T,. Epigenetic regulation of BMP7 in the regenerative response to ischemia. J. Am. Soc. Nephrol. 2008; 19: 1311-1320.
58. Marumo T, Hishikawa K, Yoshikawa M, Hirahashi J, Kawachi S, Fujita T,. Histone deacetylase modulates the proinflammatory and -fibrotic changes in tubulointerstitial injury. Am. J. Physiol. Renal Physiol. 2010; 298: F133-141.
59. Zager RA, Johnson AC, Becker K,. Acute unilateral ischemic renal injury induces progressive renal inflammation, lipid accumulation, histone modification, and 'end-stage' kidney disease. Am. J. Physiol. Renal Physiol. 2011; 301: F1334-1345.
60. Cianciolo CC, Skrypnyk NI, Brilli LL, et al. Histone deacetylase inhibitor enhances recovery after AKI. J. Am. Soc. Nephrol. 2013; 24: 943-953.
61. Novitskaya T, McDermott L, Zhang KX, et al. A PTBA small molecule enhances recovery and reduces postinjury fibrosis after aristolochic acid-induced kidney injury. Am. J. Physiol. Renal Physiol. 2014; 306: F496-504.
62. Bayrak O, Uz E, Bayrak R, et al. Curcumin protects against ischemia/reperfusion injury in rat kidneys. 2008; 26 (3): 285-291.